Gressner A M
Biochem Pharmacol. 1983 Mar 1;32(5):883-8. doi: 10.1016/0006-2952(83)90592-0.
The effect of the Ca2+-calmodulin antagonist trifluoperazine on the elevation of phosphorylation of rat liver small ribosomal subunit protein S6 induced by the hepatotoxic agent D-galactosamine has been studied. Trifluoperazine applied in various doses (1-100 mg/kg body wt) before injection of D-galactosamine into the rat does not reverse the strong increase in phosphorylation promoted by D-galactosamine. Instead, trifluoperazine has been identified as a potent stimulator of S6 phosphorylation in normal rat liver in vivo without causing significant changes in the cyclic AMP content of liver and the overall rate of liver protein synthesis. Both drugs, however, were not effective in stimulating the incorporation of [32P]phosphate into microsomes or crude ribosomes in liver slices in vitro. The results suggest that a calmodulin-activated protein kinase probably is not primarily engaged in S6 phosphorylation produced by D-galactosamine. However, further in vitro studies are needed to reach a definite conclusion.
研究了Ca2+-钙调蛋白拮抗剂三氟拉嗪对肝毒性药物D-半乳糖胺诱导的大鼠肝脏小核糖体亚基蛋白S6磷酸化升高的影响。在给大鼠注射D-半乳糖胺之前,应用不同剂量(1-100mg/kg体重)的三氟拉嗪并不能逆转D-半乳糖胺促进的磷酸化的强烈增加。相反,三氟拉嗪已被确定为正常大鼠肝脏体内S6磷酸化的有效刺激剂,而不会引起肝脏环磷酸腺苷含量和肝脏蛋白质合成总速率的显著变化。然而,这两种药物在体外均不能有效刺激[32P]磷酸盐掺入肝切片中的微粒体或粗核糖体。结果表明,钙调蛋白激活的蛋白激酶可能不是D-半乳糖胺产生的S6磷酸化的主要参与者。然而,需要进一步的体外研究才能得出明确的结论。